Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
The most striking pattern in recent filings covers Hong Kong and Chinese-listed stocks, with Viva China Holdings disclosing two open-market purchases in Li Ning worth a combined $64.1M. The trades, filed on 7 September, covered 37.7 million shares bought on 1 and 2 September. Viva China is the holding vehicle of Li Ning's founder, making these discretionary buys by the company's originator, a strong signal of confidence at current prices.
JPMorgan Chase filed as a 10% owner buying $66.2M worth of Pharmaron Beijing shares on 2 September, while also disclosing large sales across Kingdee International, Sunny Optical, and Midea Group. These are custodial and structured positions rather than directional bets; the buys and sells reflect client flow rather than house conviction.
BlackRock filed sizable reductions in Kingdee ($137.4M) and China Ruyi Holdings ($54.0M) on the same date cluster, consistent with index-driven portfolio rebalancing rather than a negative view on individual names.
On the executive side, CEO, CFO, and Director-level trades above $2M were present across the filing window but could not be isolated to US-listed names; the first-party SEC EDGAR tables were unavailable in this environment, limiting US insider analysis to the vendor dataset, which covers non-US markets most completely.
The cleanest takeaway: Li Ning's founder is buying his own stock in size. That is the trade worth watching.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
